SCHEMBL644143

SCHEMBL644143

CS(=O)(=O)c1ccc(Oc2cc(C(=O)O)cc(C(=O)O)c2C=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.44
APEX1 P27695 1/20 0.44
CTDSP1 Q9GZU7 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
PTGS2 P35354 2/20 0.42
LMNA P02545 1/20 0.40
HAO1 Q9UJM8 1/20 0.40
AKR1C3 P42330 2/20 0.39
SCN9A Q15858 1/20 0.39
SLC6A4 P31645 1/20 0.38
TTR P02766 1/20 0.38
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
GFER P55789 1/20 0.36
ERN1 O75460 1/20 0.36
GCK P35557 1/20 0.36
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL643234 0.88 POLB (0.45) POLBAPEX1CTDSP1L3MBTL1PTGS2
SCHEMBL643235 0.88 POLB (0.45) POLBAPEX1CTDSP1L3MBTL1PTGS2
SCHEMBL645157 0.82 PTGS2 (0.42) PTGS2AKR1C3SCN9ASLC6A4ERN1
SCHEMBL645253 0.80 POLB (0.40) POLBAPEX1CTDSP1L3MBTL1PTGS2
SCHEMBL9902848 0.76 GCK (0.49) POLBAPEX1CTDSP1L3MBTL1PTGS2
SCHEMBL1107719 0.76 MEN1 (0.58) POLBAPEX1CTDSP1L3MBTL1PTGS2
SCHEMBL2643772 0.72 GCK (0.42) POLBAPEX1CTDSP1L3MBTL1PTGS2
SCHEMBL2644828 0.72 GCK (0.42) PTGS2HAO1GCK
SCHEMBL2645481 0.72 GCK (0.46) POLBAPEX1CTDSP1L3MBTL1PTGS2
SCHEMBL2644024 0.72 PTGS2 (0.43) POLBAPEX1CTDSP1L3MBTL1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463283-B1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases PFIZER PROD INC (US) 2014-06-11 EP disclosed
EP-2010520-B1 HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PROD INC (US) 2012-09-12 EP disclosed
EP-2463283-A1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases Pfizer Products Inc. (US) 2012-06-13 EP disclosed
US-8119624-B2 Fused phenyl amido heterocyclic compounds PFIZER INC. (US) 2012-02-21 US disclosed
US-20110039821-A1 Fused Phenyl Amido Heterocyclic Compounds PFIZER INC 2011-02-17 US disclosed
US-7842713-B2 Fused phenyl amido heterocyclic compounds PFIZER INC (US) 2010-11-30 US disclosed
EP-2010520-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES Pfizer Products Incorporated (US) 2009-01-07 EP disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed
WO-2007122482-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PRODUCTS INC. (US) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039821-A1 Fused Phenyl Amido Heterocyclic Compounds GCK, GCKR, HK1 POLB 4200/4885APEX1 4450/4885CTDSP1 4517/4885
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS GCK, GCKR, HK1 POLB 4200/4885APEX1 4450/4885CTDSP1 4517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.